Executive leadership team
Itziar Canamasas, PhD.
CEODr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School and IMD Business School.
Gabriela Jiménez, PhD.
Co-Founder & COODr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies BSM, EADA business school and IESE. She is experienced in business development, drug development and biomarker discovery.
Oriol Casanovas, PhD.
Co-Founder & CSODr. Casanovas is an internationally renowned biomedical researcher with extensive knowledge and experience in basic and translational research focused on determining the consequences of adaptation and resistance to therapies against cancer.
Advisor team
Bart Huisken, MBA.
Co-Founder & Business StrategyRichard Roberts, PhD.
Medicinal Chemistry AdvisorRamón Salazar, MD, PhD.
Clinical Oncology ExpertTodd Snowden
IVD Strategy AdvisorResearch team
Our academic founders have played a key role in demonstrating that resistance to cancer therapy occurs in response to adaptive mechanisms of tumor cells.
We are part of the Program Against Cancer Therapeutic Resistance (ProCURE)
We research resistance mechanisms and tumor malignization
We are always looking for new talent to join our team